Find information on thousands of medical conditions and prescription drugs.

Valsartan

Valsartan (Diovan®) is an angiotensin II receptor antagonist, acting on the AT1 subtype. It is used to treat high blood pressure, congestive heart failure, and may be used to treat chronic renal failure.

Administration

Oral tablets, containing 40 mg, 80 mg, 160 mg or 320 mg of valsartan. Usual dosage ranges from 40-320 mg daily. Diovan HCT® contains a combination of valsartan and hydrochlorothiazide.

Side effects

Most commonly, headache and dizziness.

  • More information in PuMed for Valsartan
Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


VALUE trial — 23% drop in new-onset diabetes with valsartan
From Diabetes and Primary Care, 9/22/04

A 23% relative risk reduction in new-onset diabetes over 4 years was observed in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial presented at the European Society of Hypertension meeting on 14 June and published simultaneously online by The Lancet. The 15,245-patient trial set out to see if, for the same blood-pressure control, an angiotensin receptor blocker-based treatment regimen using valsartan would reduce cardiac morbidity and mortality more than a calcium channel blocker-based regimen using amlodipine in hypertensive patients at high cardiovascular risk. The answer was negative. Patients receiving amlodipine achieved better and earlier blood pressure control, significantly reducing their risk of fatal and non-fatal myocardial infarction more than those on valsartan-based treatment (p=0.02).

[ILLUSTRATION OMITTED]

Valsartan's reduction in new-onset diabetes was statistically significant. However, some experts said that similar reductions were found in the LIFE (Losartan Intervention for Endpoint reduction in hypertension) trial and in most recent antihypertensive trials. Professor Bryan Williams of Leicester University said the study confirms people at high risk of developing diabetes are better off avoiding blood pressure-lowering combinations primarily using beta-blockers or diuretics. The real importance of VALUE was demonstrating the importance of establishing effective blood pressure control quickly, he commented.

COPYRIGHT 2004 S.B. Communications
COPYRIGHT 2004 Gale Group

Return to Valsartan
Home Contact Resources Exchange Links ebay